Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses

Journal of Virology

Volumn 75, Issue 18, 2001, Pages 8649-8659

  Leen, A ^a   Meij, P ^a   Redchenko, I ^a   Middeldorp, J ^a   Bloemena, E ^a   Rickinson, A ^a   Blake, N ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 3C; GAMMA INTERFERON; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TH1 CELL; VIRUS CARRIER; VIRUS INFECTION; VIRUS LATENCY;

EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; PEPTIDES; TH1 CELLS; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

EID: 0034892688     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.18.8649-8659.2001     Document Type: Article

References (49)

1. Functional diversity of helper T lymphocytes
2. Dendritic cells and the control of immunity
3. Sequence polymorphisms between latent membrane proteins LMP1 and LMP2A do not correlate in EBV-associated reactive and malignant lympho-proliferations
4. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
5. The importance of exogenous antigen in priming the human CD8+ T cell response: Lessons from the EBV nuclear antigen EBNA1
6. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains
7. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo
8. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells
9. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure
10. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
11. Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen
12. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1
13. Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera
14. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr latent origin of DNA replication
15. The structural requirements for class II (I-Ad)-restricted T cell recognition of influenza hemagglutinin: B cell epitopes define T cell epitopes
16. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas
17. Promiscuous and allele-specific anchors in HLA-DR-binding peptides
18. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
19. Growth inhibition of Epstein-Barr virustransformed B cells by anti-HLA-DR antibody L243: Possible relationship to L243-induced down-regulation of CD23 antigen expression
20. Analysis of Epstein-Barr virus gene polymorphism in normal donors and in virus-associated tumors from different geographic locations
21. Localisation of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development
22. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
23. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes
24. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class 11 pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing
25. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs
26. Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy
27. Antibodies to LMP2A/2B in EBV-carrying malignancies
28. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
29. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases
30. Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man
31. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
32. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV); implications for the immune control of EBV-positive malignancies
33. Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo
34. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4+ T lymphocytes
35. The cellular basis for viral-induced immunodeficiency: Analysis by monoclonal antibodies
36. Epstein-Barr virus
37. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
38. Mutational analysis of human papillomavirus E4 proteins: Identification of structural features important in the formation of cytoplasmic E4/cytokeratin networks in epithelial cells
39. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
40. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus
41. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: Identification of four variants among wild-type EBV-isolates
42. Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis
43. + T-lymphocyte response to Epstein-Barr virus nuclear antigen 1
44. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory
45. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
46. T-cell clones
47. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases
48. Viral immune evasion due to persistence of activated T cells without effector function